Dusquetide, a novel Innate Defense Regulator, modulates the innate immune system at a key convergence point in intracellular signaling pathways and has demonstrated activity in both reducing inflammation and increasing clearance of bacterial infection. Innate immunity has also been implicated in the pathogenesis of oral mucositis (OM), a universal toxicity of chemoradiation therapy (CRT). Testing the hypothesis that dusquetide can mitigate the development and duration of OM, preclinical studies have been completed and correlated with interim results from a Phase 2 clinical study in patients undergoing CRT for head and neck cancer. Dusquetide reduced the duration of OM in mouse and hamster models by approximately 50%, which was recapitulated by the 50% reduction of severe OM (SOM) in the Phase 2 trial. A reduction in the clinical rate of infection was also observed, consistent with previously reported preclinical studies. In aggregate, these results not only demonstrate the safety and efficacy of dusquetide in addressing this unmet medical need, but also provide proof of concept for the translation of dusquetide action between animal models and the human clinical setting, and further support the contention that innate immunity is an important driver for the initiation and continued impact of OM.
Introduction
Oral mucositis (OM) is a universal toxicity of chemoradiation therapy (CRT) used for cancers of the oral cavity, oropharynx and larynx, whose incidence continues to increase despite aggressive intervention (Ryerson et al., 2016) . Severe OM (SOM) occurs in almost 75% of these patients and is among the most debilitating and painful side effects related to treatment (Elting et al., 2009) . SOM is associated with increased opioid use, weight loss, reliance on supplemental feeding and hydration, breaks in treatment, unplanned office, or emergency room visits and frequent hospitalizations resulting in an incremental cost of $18,000 per patient (Nonzee et al., 2008) . OM, including SOM, is a common feature of many other treatment regimens for cancers other than head and neck, albeit generally occurring with lesser frequency and duration (Peterson et al., 2011; Kudrimoti et al., 2008) .
There are no Food and Drug Administration (FDA)-approved drugs to ameliorate SOM in patients with head and neck squamous cell carcinoma. The only approved therapy for oral mucositis in any context is palifermin (Nguyen et al., 2015; Lucchese et al., 2016) , a tissue growth factor that is approved for use in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support. However, palifermin is associated with a potential risk of stimulating/encouraging solid tumor proliferation (McDonnell and Lenz, 2007) and is therefore used in hematologic cancers only. Other approaches, such as photobiomodulation, have also been evaluated, including in head and neck cancer patients (Fekrazad and Chiniforush, 2014) ; although, concerns have been raised here as well about the potential negative impact on tumor control (Sonis et al., 2016) As the biological complexity of OM has become increasingly clear, preclinical and clinical data have accumulated supporting a role for an exaggerated innate immune response as a key initiating event and a continuing contributor in its pathogenesis (Sonis, 2004) . The response of the innate defense system to the resulting CRT-induced damage-associated molecular patterns (DAMPs) results in an inflammatory cascade that culminates in apoptosis of epithelial stem cells, mucosal atrophy and ultimately ulceration (Sonis, 2004 (Sonis, , 2007 Sonis et al., 2007; Logan et al., 2007) . The resulting ulceration continues to send DAMP signals, as well as potential pathogen-associated molecular pattern (PAMP) signals due to infection, further exacerbating the inflammatory response. Therefore, the innate immune response is a potential target to attenuate both the incidence and duration of CRT-induced OM (Sonis, 2004 (Sonis, , 2007 .
Dusquetide (SGX942) is a first-in-class Innate Defense Regulator (IDR) that modulates the innate immune response to both PAMPs and DAMPs by binding to p62, a key adaptor protein that functions downstream to the key sensing receptors (e.g., toll-like receptors [TLRs] , etc.) that trigger innate immune activation (Yu et al., 2009 ). There are no other drug candidates which target the p62 protein. When the innate immune sentinel cell is activated, the presence of dusquetide modulates the cellular signaling from a pro-inflammatory, pro-macrophage response to an antiinflammatory, heightened pro-macrophage response. This leads to decreased inflammation with increased bacterial clearance and tissue healing (North et al., 2016; Scott et al., 2007; Yu et al., 2009 ). Importantly, both circulating and tissue resident innate immune cells respond to dusquetide treatment, making it useful even in the context of immunosuppression (North et al., 2016) . Dusquetide therefore has the potential to address each of the stages of the pathogenesis of oral mucositis, decreasing the innate immune amplification of the damage signaling (and subsequent exacerbation of tissue damage), decreasing the incidence and increasing the clearance of any secondary infections and aiding in the tissue healing and resolution of mucositis. As such, dusquetide would be expected to decrease the duration of OM. Importantly, dusquetide does not mitigate the direct damage done by CRT to the tumor (or the surrounding normal tissue).
The safety of single and multiple ascending doses of intravenous (IV) dusquetide was demonstrated in a placebo-controlled study of 84 healthy human volunteers, in which dusquetide was found to be safe and well tolerated (North et al., 2016) . In the groups receiving multiple doses, most adverse events (AEs) were related to minor infusion/venipuncture reactions. Other reported AEs were somnolence (4/20 dusquetide patients, 2/10 placebo patients), alanine aminotransferase (ALT) elevation (3/20 dusquetide patients, 1/10 placebo patients), and back pain (3/20 dusquetide patients, 1/10 placebo patients). In vitro exposure to endotoxin of peripheral blood cells from the same cohort, demonstrated an increase in antiinflammatory markers and a decrease in inflammatory markers following administration of low doses (0.15-2.0 mg/kg) of dusquetide relative to those subjects exposed to placebo (North et al., 2016) . Blood from patients exposed to high doses (3.0-8.0 mg/kg) of dusquetide, on the other hand, had responses similar to those receiving placebo (North et al., 2016) .
Given the proposed role of innate immunity in mucositis, dusquetide was tested first in preclinical models of mucositis. Subsequently, dusquetide was assessed in a well-characterized clinical setting in a Phase 2a study specifically focusing on oral mucositis in order to evaluate dusquetide's safety, efficacy and consistency of the response with preclinical results.
Materials and methods

Animal models
All experimental procedures using animals were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and performed in IACUC-approved research facilities with the approval of the facility's Animal Care and Use Committee (approval numbers 09-1215-03, 09-1215-04 and 10-0527-1 from the Biomodels LLC IACUC).
Mouse model of chemotherapy-induced mucositis
5-fluorouracil (60 mg/kg IP) was administered to male C3H/HeN mice on Days −4 and −2. On Day 0, a chemical burn was applied to the underside of the mouse tongue, inducing mucositis which generally peaked on Day 2 (Sonis et al., 1990) . Mouse tongues were scored from 0 to 5 for mucositis daily from Days 1 to 14 by 2 blinded observers. Body weights were also measured daily and colitis severity was determined by video endoscopy on Days 4 and 7. Dusquetide (25 mg/kg IV) was administered after chemotherapy on Days −1, 2 and 5 in 3 independent experiments and the average duration as a percent of the placebo (saline) response was averaged across the 3 experiments. The dusquetide response was statistically significant (p ≤ 0.01) in each experiment.
Hamster model of fractionated radiation-induced OM
Canulated male Golden Syrian hamsters were treated with 7.5 Gy of radiation, directed at the everted left cheek pouch, on Days 0, 1, 2, 3, 6, 7, 8 and 9 (Ara et al., 2008) . Mucositis was evaluated every second day by 2 blinded observers between Days 7 and 35, with peak mucositis severity generally occurring around Day 19. Dusquetide (25 mg/kg IV) was administered either every third day between Days 0 and 33 (Q3d D0-33; evaluated in 2 experiments), every 3rd day between Days 6 and 33 (Q3d D6-33; evaluated in 1 experiment), on days of radiation (evaluated in 2 experiments), or every third day during radiation treatment (i.e., Days 0, 3, 6 and 9; evaluated in 1 experiment). Results are presented as the percent duration relative to the placebo (saline) response in each experiment, and are averaged over 2 experiments where possible.
Mouse model of colitis
Dextran sulfate sodium (DSS) was administered as a 3% DSS solution in the drinking water of male C57BL/6 mice from Days 0 to 5 of the study (Hamilton et al., 2011) . Colitis was monitored by video endoscopy on Days 7, 14 and 21. Dusquetide (25 mg/kg IV) was administered every third day from Days 0 to 18 (Q3d d0-18), from Days 3 to 18 (Q3d d3-18) or from Days 6 to 18 (Q3d d6-18).
Histopathology of the colon was evaluated on Day 21 (Supplemental Fig. 1 ). Statistical analysis was undertaken using t-tests and an asterisk indicates statistically significant differences from placebo (saline) control (p < 0.05).
Mouse tumor xenograft model
Sixty female nude mice were implanted with estrogen pellets and 2-3 days later 5 × 10 6 MCF-7 cells were implanted subcutaneously. Once tumors reached an average size of 100 mm 3 , the animals were randomized into 6 groups of 10 animals and received control, dusquetide, paclitaxel + vehicle, paclitaxel + dusquetide, radiation therapy + vehicle or radiation therapy + dusquetide. Dusquetide (25 mg/kg) or vehicle (saline) was administered IV on Days 0, 4, 7, 10, and 14. Paclitaxel (6 mg/kg IP) or radiation therapy (2 Gy/Day) was undertaken on Days 1, 3 and 5. Tumors were measured (L × W × W/2) on Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 and 29 . An unexpected number of deaths occurred in all treatment groups, unrelated to treatment with study drug, and thus tumor volumes can only be reliably interpreted up to Study Day 12.
Peptide
Dusquetide (acetate salt, research name: SGX94) was synthesized by solution phase synthesis (PPL, Inc.). Peptide purity was analyzed by high performance liquid chromatography (HPLC) and was typically greater than 97%. Dusquetide was formulated in aqueous solution for intravenous (IV) administration (drug product research name: SGX942).
Phase 2a clinical study
The primary objective of this exploratory trial was to assess the safety and effectiveness of dusquetide compared to placebo in attenuating the duration and/or incidence of SOM in patients undergoing CRT for head and neck cancer. Secondary objectives included assessing the effectiveness of the drug in reducing ulcerative oral mucositis (UOM) and determining which patient baseline characteristics define subpopulations in which dusquetide had particular effectiveness. The null hypothesis was that dusquetide would not positively impact the duration and/or severity of OM.
Subjects
This study was conducted in the United States with 21 of 27 sites enrolling at least 1 subject, in accordance with the principles of the Declaration of Helsinki and with the approval of institutional review boards at each center. This Phase 2a study was registered with ClinicalTrials.gov (NCT02013050). Patient enrollment was completed between December 2013 and August 2015.
Inclusion/exclusion criteria: Eligible patients were at least 18 years of age with locally advanced (Stages III-IVA/B) squamous cell carcinoma of the oral cavity or oropharynx, and adequate organ function and performance status. All patients were scheduled to receive a continuous course of conventional intensity modulated radiation therapy (IMRT) administered as single daily fractions of 2.0 to 2.2 Gy, with a cumulative radiation dose between 55 and 72 Gy at each of at least 2 oral sites concurrent with cisplatin administered either weekly (30-40 mg/m 2 for up to 7 doses) or every third week (80-100 mg/m 2 for 3 doses). Patients who had received surgery were eligible if the surgery had been performed within 10 weeks prior to the planned initial dose of study drug. Patients with prior head and neck radiotherapy, chemotherapy within 12 months, scheduled to receive cetuximab, clinically significant organ system dysfunction, or who were pregnant, breast-feeding, or participating in another interventional clinical trial were not eligible. All patients signed written informed consent prior to study enrollment.
Study design
This was a double blind, placebo-controlled trial. The initial sample size of 78 patients for this exploratory study was set based the assumption that SGX942 treated patients would have a median duration of SOM (WHO Grade 3 or higher) of about 11 days and placebo treated subjects would have a median duration of SOM of about 27 days. Using these assumptions and no adjustment for multiple testing, a total of 21 placebo patients and 27 total patients in the SGX942 1.5 mg/kg group, would yield at least 88% power to detect a statistical difference (27 days vs. 11 days) with alpha = 0.1 using a log-rank test.
Patients received study drug (i.e., dusquetide or placebo given IV) within 3 days of starting radiation treatment and then twice a week (every 3rd day ± 1 day) while receiving radiation therapy. The initial dose escalation phase of the trial assessed the safety of dusquetide or placebo given for a maximum of 14 doses to consecutive cohorts of six patients randomized to dusquetide or placebo with equal numbers of patients (i.e., 3 placebo: 3 SGX942). Doses of dusquetide used were 1.5, 3.0 and 6.0 mg/kg. After completion of the treatment course within a filled cohort, the data were reviewed by an independent Data Review Committee (DRC) consisting of a statistician, oncologist and preclinical researcher. Once the DRC determined that there were no safety concerns, the next cohort receiving the next higher dose of dusquetide was started. In the second portion of the trial, patients were randomized to receive 1.5 mg/kg dusquetide, 6.0 mg/kg dusquetide, or placebo given twice weekly throughout radiation therapy and randomized 4:4:1 respectively to yield an approximately equal distribution across the placebo, 1.5 and 6.0 mg/kg treatment groups over the course of the entire study. Following a pre-specified interim analysis by the DRC after 84 patients had completed their therapy, an additional 27 patients were enrolled into the trial, and randomized equally to 1.5 mg/kg dusquetide or placebo at select sites (Supplemental Fig. 2 ).
All patients receiving any study drug were included in the safety analyses. Because the incidence of OM is highly correlated to the cumulative radiation dose received, the primary efficacy population was prospectively defined as consisting of patients receiving a minimum cumulative radiation dose of 55 Gy to the oral cavity or oropharynx. For the efficacy analyses, patients for both parts of the study that receive the same dose of dusquetide were pooled. Because only 3 patients were randomized to the 3.0 mg/kg dusquetide, no effectiveness conclusions can be drawn at this dose.
Assessment of OM, AEs, infections, and tumor response
The severity of OM was determined using WHO criteria (Sonis 2004; World Health Organization, 1979) and was assessed by trained staff twice weekly from baseline to the last study drug treatment. If UOM persisted (WHO score ≥2) at last study drug treatment, OM was further assessed weekly thereafter to the 1-month follow-up visit, at which point all subjects had a follow-up evaluation. SOM was defined as a WHO score of ≥3 and the duration of SOM defined as the time between the initial assessment of a WHO score ≥3 to the last time a score of ≥3 was noted. Any patient with unresolved SOM had their duration censored at the time of the last assessment of OM. Standard clinical chemistry and hematology studies were performed using samples obtained at baseline, at 2, 4 and 6 weeks, on the last day of study drug treatment, and 1 month after completion of treatment. AEs were recorded at each visit, including all clinical diagnoses of infection and the investigator's assessment as to whether the infection was severe. Repeat radiologic scans were obtained 1 month following completion of treatment and were compared to the staging scans using the RECIST 1.1 criteria (Eisenhauer et al., 2009) .
Duration of SOM, severity-weighted duration area under the curve (AUC), and time to onset were compared using a log-rank test. The incidence of OM and incidence of infections was compared using Fisher's exact test. The objective of this exploratory study was to assess trends in biological efficacy and as such the statistical significance threshold was prospectively set at p < 0.10.
Results
Preclinical data
The impact of dusquetide on mucositis was assessed in the context of chemotherapy-induced mucositis, assessing responses in both the oral cavity and the lower gastrointestinal (GI) tract, and in the context of fractionated radiation, directed at the oral cavity alone. In each case, up to a 50% reduction in the duration of OM was observed (Fig. 1a,b,c) . Similar reductions in AUC were also observed (Supplemental Fig. 3 ). The impact of dose was evaluated in each study by assessing dosing time and/or frequency. In general, repeated administration of dusquetide was not associated with an increased benefit (e.g., Fig. 1a) , suggesting that more frequent dosing was not beneficial. This finding is consistent with previous studies in bacterial infection models (North et al., 2016) .
To further investigate the extent to which dusquetide may mitigate damage in the lower GI tract, a more severe DSS colitis mouse model was utilized (Fig. 1d) . By Day 14, all 3 dusquetide treatment regimens demonstrated a statistically significant reduction in endoscopic colitis severity score; however, reduction in Day 7 scores were only observed in groups which had received at least 2 doses of dusquetide by Day 7. On Day 21 all 3 dusquetide groups appeared to be responding similarly. Histopathology on Day 21 indicated that some dusquetide treated groups had statistically significantly decreased edema and necrosis, whereas other dusquetide treated groups had similar responses which did not reach statistical significance (Supplemental Fig. 1) .
Pharmacodynamically, dusquetide modulates the innate defense system and thereby alters the consequent toxicity of radiation or chemotherapy. Given the proposed role of the innate defense system in radiation treatment of tumors, specific evaluation of the impact of dusquetide on radiation tumor treatment was undertaken using a tumor xenograft model with likelihood to demonstrate an innate immune mediated interference. Thus, studies were undertaken in nude mice with a minimally disturbed innate immune system, in which dusquetide had previously demonstrated efficacy (North et al., 2016) , using the MCF-7 tumor line (i.e., breast cancer cell line). MCF-7 cells express p62, the target of dusquetide action (Abcam Product Datasheet, 2016) , and are Beclin +/− and therefore autophagy deficient, making them highly sensitive to interference with p62, a central protein in the autophagic machinery (Aita et al., 1999; Rosenfeldt and Ryan 2009) .
Treatment of MCF-7 tumor xenografts with dusquetide showed no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation. Treatment with dusquetide did not interfere with radiation or chemotherapy (i.e., paclitaxel) treatment of MCF-7 tumor growth. Indeed, a trend towards an additive suppression of tumor growth was observed (Fig. 2) .
Phase 2a clinical study
Patients
A total of 111 patients were enrolled between December 2013 and August 2015 at 21 sites (Fig. 3) . Five patients in each of the placebo, 1.5 mg/kg dusquetide, and 6.0 mg/kg dusquetide dose groups did not receive a cumulative dose of at least 55 Gy of radiation to the oral cavity or oropharynx and were not evaluable (i.e., were not a part of the modified Intent to Treat population) (Fig. 3) .
Of the 96 evaluable patients, the median age was 58.5 years, 81% were men, 34% had oral cavity and 66% had oropharyngeal tumors, 76% had Stage IVA disease, 53% had tumors that were human papilloma virus (HPV) positive based on p16 immunostaining, and 28% received surgery. The treatment groups were well balanced with respect to their baseline characteristics (Table 1) .
Safety
The rates and types of reported AEs, serious AEs, changes in vital signs, and laboratory abnormalities were similar across dose groups. Specific assessment of treatment-emergent AEs suggested a potential shift in some hematology endpoints (e.g., white blood cell counts, anemia) ( Table 2 ). To test if this expected, unavoidable side effect of aggressive CRT was being differentially reported by different sites (ascertainment bias), the lowest white blood cell count for each patient was identified and this nadir value plotted for each dose group. The resulting plot shows similar distributions of nadir white blood cell counts in the dose groups (Fig. 4a) . This suggests that the discrepancies between dose groups reported as having "white blood cell disorder" AEs can be attributed to inconsistency between site and/or physician reporting and not an actual concern.
Another numeric difference is seen in patients with reported anemia. The nadir measurements for anemia are shown in Fig. 4b,c,d , also indicating no association with anemia and dusquetide (SGX942) dosing.
Efficacy
Patients receiving 1.5 mg/kg of dusquetide had a 50% reduction in their median duration of SOM compared to the placebo group (18 versus 9 days for the placebo and dusquetide groups, respectively; Fig. 5a ). This finding was supported by a 39% reduction in the median AUC for the WHO Grade-time calculation (35.5 versus 21.8 score-days for the placebo and dusquetide groups, respectively), a 71% reduction in the rate of SOM through 1-month after completion of treatment (from 21% in the placebo group to 5% in the dusquetide group) and a 7% relative reduction in the incidence of SOM when compared to placebo (from 74% in the placebo group to 69% in the dusquetide group; Supplemental Table 1 ). In the 6.0 mg/kg group, the results were inconsistent across outcomes (Supplemental Table  1 ).
Several subpopulations of patients were prospectively identified for further analyses. The duration of SOM of placebo-treated patients was greater among individuals treated with cisplatin every third week (80-100 mg/m 2 ; 30 days) compared to placebo-treated patients treated with weekly cisplatin (30-40 mg/m 2 ; 10 days). In those patients receiving cisplatin every third week, there was a 67% decrease in the median duration of SOM (i.e., from 30 to 10 days in the placebo and dusquetide 1.5 mg/kg dose groups, respectively; Fig. 5b ), which was associated with a 51% reduction in the median AUC WHO Grade-time calculation, and an 18% relative reduction in incidence of severe OM compared to placebo (Supplemental Table  1 ). Among patients receiving weekly 30-40 mg/m 2 cisplatin, the median duration of SOM was decreased 50% from 10 days in the placebo group to 5 days in the 1.5 mg/kg dusquetide group, which was associated with a 55% reduction in the median AUC WHO Grade-time calculation.
Improvements in UOM (WHO grade ≥2) seen in the 1.5 mg/kg dusquetide dose group were similar to those for SOM but the magnitude of the observed trends was less. The median duration was decreased by 12% and the median AUC WHO Grade-time calculation was decreased by 22%, with correspondingly stronger affects in the subpopulation receiving every third week cisplatin (median dura- tion decreased by 22% in the dusquetide 1.5 mg/kg group [51 days] relative to placebo [65 days]) (Supplemental Table 1 ).
Reported infections
Infections were monitored as AEs from the baseline visit until 1 month after the last study drug treatment. The rate of clinically diagnosed infections was reduced in patients in the dusquetidetreated groups compared to placebo controls ( Fig. 5c ; Supplemental Table 2 ).
Tumor response
Tumor status was examined 1 month after completion of treatment using the RECIST 1.1 grading system (Eisenhauer et al., 2009 ). Dusquetide did not impair tumor response. In addition, 47% of subjects in the placebo group and 63% in the 1.5 mg/kg dose group were reported as having a "complete response" ( Fig. 5d ; Supplemental Table 3 ) to CRT.
Discussion
Dusquetide consistently reduced the duration of OM by approximately 50% in 2 key preclinical index models of mucositis (Fig. 1a,b) . Efficacy was independent of the triggering event causing the OM (i.e., radiation, chemotherapy), consistent with the hypothesis that the pathogenesis of mucositis is tied to the response of the innate immune system to the damage rather than the underlying cause of damage directly (Fig. 1c) . Similarly, efficacy was also observed in both the oral cavity and the lower GI tract, again consistent with the presumption that oral and GI mucositis are driven by similar mechanisms in different locations (Keefe, 2007) . In another model of chemotherapy-induced colitis, dusquetide was similarly dosed every third day and again found to mitigate damage, whether initiated at the same time, during or after the DSS (Fig. 1d ). In this model, efficacy was linked to administering at least 2 doses of dusquetide. Even in the context of continuing damage (e.g., fractionated radiation, DSS-induced colitis), dusquetide treatment was shown to be effective (Fig. 1a,c) .
Previous studies in rodent infection models (North et al., 2016) have identified a dose level between 25 and 50 mg/kg (corresponding to a human equivalent dose between 2 and 4 mg/kg) every second or third day as optimal. Doses higher than 50 mg/kg were not tested in mouse efficacy studies due to dosing limitations in the mouse. Similar results were observed in these studies, where dosing every second or third day was superior to daily dosing (Fig. 1a) . In each case, dusquetide was efficacious when administered after the damaging stimulus was applied (e.g., after irradiation (Fig. 1a) or chemotherapy (Fig. 1b,c,d) ). This treatment modality was chosen as a mimic of the most clinically convenient treatment course.
In pharmacodynamic studies in both cynomolgus monkeys and humans, where dusquetide was administered IV and blood was drawn and evaluated directly (monkeys) or stimulated with endotoxin ex vivo (humans), higher dusquetide doses did not yield stronger responses (North et al., 2016) . In monkeys at dose levels of 3, 30 and 240 mg/kg, the responses of the anti-inflammatory IL-1ra levels were found to be highest at 3 and 30 mg/kg (corresponding to a human equivalent dose of 1-10 mg/kg) (North et al., 2016) . Similarly, in a Phase 1 clinical study, anti-inflammatory responses were highest after administration of dose levels between 0.15 and 2.0 mg/kg, while individuals receiving doses between 3.0 and 8.0 mg/kg were indistinguishable from the placebo group (North et al., 2016) . These data in aggregate clearly suggest that the adage "more is better" does not hold for this immune regulator. Hormetic, or non-monotonic, dose response curves are well known in immune biology, generally arising due to a balance of competing pathways (Liu 2003; Pearce et al., 2014) . 
Local of tumor: number (% dose group) Oral cavity 12 (32%) Given the potential role of dusquetide in immune biology, including impacting the microenvironment of the tumor, a xenograft study was conducted with a tumor cell line most likely to be sensitive to p62 (target protein) modulation. No degradation of tumor control by chemotherapy or radiotherapy was observed, and there was a trend towards increased tumor suppression (Fig. 4) . This finding is not unexpected, given the role of p62 in the tumor microenvironment, such as in the context of multiple myeloma .
Based on these findings, doses for the Phase 2a clinical study were selected to represent the 2 "profiles" observed in the Phase 1 study -one dose representing the "low dose" in the Phase 1 study (1.5 mg/kg representing the low dose range of 0.15-2.0 mg/kg) and one representing the "high dose" (6.0 mg/kg representing the high dose range of 3.0-8.0 mg/kg). While both doses were tested, efficacy was anticipated at the low dose (1.5 mg/kg) due to the antiinflammatory activity observed in the Phase 1 study and the efficacy observed in preclinical studies around this dose level (25-50 mg/kg in a mouse corresponds to 1.5-4 mg/kg in a human).
Upon discussion with FDA, an interim dose was recommended, allowing for a more gradual dose escalation. As the 3.0 mg/kg dose level was introduced for safety reasons, no efficacy analysis of this group was planned given the limited number of subjects incorporated (3 placebo, 3 dusquetide subjects only were included in this cohort). Provision was included in this Phase 2a hypothesisgenerating study for an independent DRC review of patient data prior to dose escalation (from 1.5 to 3.0 mg/kg, from 3.0 to 6.0 mg/kg and prior to proceeding with additional enrollment at 6.0 mg/kg), as well as an interim review whereupon additional subjects could be recommended to be enrolled.
Consistent with the Phase 1 study, no treatment-emergent changes in vital signs, laboratory values, AEs or serious AEs were found to be attributed to dusquetide treatment. In this population, dusquetide (SGX942) appears to be safe and well tolerated.
In the present study, the incidence of SOM in the placebo arm of 74%, the early discontinuation of patient participation in the trial of 14%, and the frequency of reported AEs are consistent with other recently published data (Nien et al., 2016; Henke et al., 2011) sug- a Safety population = all patients receiving at least one dose of study drug. gesting that the placebo group is representative of the head and neck cancer patient population. Dusquetide at the 1.5 mg/kg dose was effective in decreasing the duration of SOM in patients with squamous cell carcinoma of the oral cavity or oropharynx undergoing concomitant CRT (Fig. 5a,b) . The results in the 6.0 mg/kg dusquetide dose group compared to the placebo group are inconsistent across the various measures of SOM and across the various subpopulations ( Fig. 5a,b ; Supplemental Table 1 ), suggesting that it is not as effective in ameliorating OM as the 1.5 mg/kg dusquetide dose; however, the limited sample size in the 6.0 mg/kg group makes any conclusions uncertain. Decreased effectiveness at the 6.0 mg/kg dose level would be consistent with findings in the Phase 1 study with dusquetide, where anti-inflammatory activity was more prevalent at the lower dose level (North et al., 2016) .
The 50% reduction in the duration of SOM in patients treated with dusquetide (Fig. 5a,b) is consistent with the preclinical studies in both chemotherapy and radiation-induced oral and GI mucositis in which dusquetide reduced the peak intensity and duration of mucositis by approximately 50% in the duration of SOM (Fig. 1a,b) .
Extensive studies have been conducted with dusquetide in various preclinical models of bacterial infection (North et al., 2016) . Because dusquetide affects the host response rather than being directed at the bacteria, this drug has an effect on infections caused by gram-negative and gram-positive bacteria as well infections related to multiple resistant organisms. Dusquetide is an effective agent both prophylactically and therapeutically (North et al., 2016) . Our finding that the treated groups had fewer bacterial infections (Fig. 5c , Supplemental Table 2 ) is very consistent with preclinical animal models. Similarly, the potential reduction in tumor volume observed in preclinical studies (Fig. 4) was echoed in the increased rate of "complete resolution" tumor status at the 1-month followup visit in the Phase 2a study (Fig. 5d, Supplemental Table 3 ).
The treatment of OM has been fraught with many clinical failures, beginning with treatments targeted at infected ulcers (e.g., antibiotic mouthwashes). Further studies, including the use of DNA and RNA biomarkers (Sonis et al., 2002) , have demonstrated that OM is an inherently inflammatory condition related to the activation of the innate immune system in response to the damage caused by CRT. Under this hypothesis, treatments modulating the innate immune response have been suggested as an alternative approach. IDRs such as dusquetide address all phases of OM, decreasing the initial inflammatory response to damage, mitigating the inflammatory amplification phase, providing anti-infective activity during the ulcerative phase and potentially aiding in tissue healing through the recruitment of macrophages (Scott et al., 2007; North et al., 2016) . This exploratory Phase 2a study has further validated the underlying hypothesis regarding innate immune contribution to OM pathogenesis and has demonstrated that treatment with an IDR has the potential to not only reduce the impact of OM, but also to provide ancillary benefits of reducing infections and potentially aiding in the treatment of the underlying tumor.
The highly conserved nature of the innate immune system suggests that animal models should provide realistic models of the human clinical condition. Nonetheless, dusquetide has a unique mechanism of action, heretofore untested in the human setting. These preclinical and clinical studies have indicated that all of the biological functions observed in the preclinical setting were transferred to the clinical setting, including reduction in duration of OM and reduction in infection. These findings provide biological proof of concept for the IDR platform and indicate that other preclinical IDR activity is more likely to translate to the clinical setting.
In conclusion, dusquetide was shown to be effective, reducing the duration of SOM in head and neck cancer patients, and safe and well tolerated in an exploratory Phase 2a study. The results of this clinical study were consistent with preclinical findings, including reduction in OM, reduction in acute inflammation and reduction in the incidence of infection.
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